

Eine Konsensus-Erklärung der European Psychiatric Association (EPA) zu kardiovaskulären Erkrankungen und Diabetes bei Patienten mit einer schweren psychischen Erkrankung

Unterstützt von der European Association for the Study of Diabetes (EASD) und der European Society of Cardiology (ESC)*

M. De Hert^a, J.M. Dekker^b, D. Wood^c, K.G. Kahl^d, R.I.G. Holt^e, H.-J. Möller^f

Literatur

- Allison DB, Mentore JL, Heo M, Chandler LP, Cappelleri JC, Infante MC, et al. Antipsychotic-induced weight gain: a comprehensive research synthesis. *Am J Psychiatry* 1999; 156 (11): 1686–96.
- Allison DB, Newcomer JW, Dunn AL, Blumenthal JA, Fabricatore AN, Daumit GL, et al. Obesity among those with mental disorders: a National Institute of Mental Health meeting report. *Am J Prev Med* 2009; 36 (4): 341–50.
- Álvarez-Jiménez M, Hetrick S, González-Blanch C, Gleeson J, McGorry P. Non-pharmacological management of antipsychotic-induced weight gain: systematic review and meta-analysis of randomised controlled trials. *Br J Psychiatry* 2008; 193: 101–7.
- American Association of Clinical Endocrinologists 2007. Medical Guidelines for Clinical Practice for the Management of Diabetes Mellitus. *AAACE Diabetes Mellitus Guidelines*. *Endocr Pract* 2007; 13 (Suppl. 1): 3–68.
- American Diabetes Association. Consensus Development Conference on Antipsychotic Drugs and Obesity and Diabetes. *Diabetes Care* 2004; 27: 596–601.
- American Diabetes Association. Standards of medical care in diabetes – 2009. *Diabetes Care* 2009; 32 (Suppl. 1): S13–61.
- American Diabetes Association. Diagnosis and Classification of Diabetes Mellitus. *Diabetes Care* 2009; 32 (Suppl. 1): S63–7.
- Angst F, Stassen HH, Clayton PJ, Angst J. Mortality of patients with mood disorders: follow-up over 34–38 years. *J Affect Disord* 2002; 68 (2–3): 167–81.
- Arango C, Bobes J, Aranda P, Carmena R, García-García M, Rejas J, et al. A comparison of schizophrenia outpatients treated with antipsychotics with and without metabolic syndrome: Findings from the CLAMORS study. *Schizophr Res* 2008; 104 (1–3): 1–12.
- Barnett AH, Mackin P, Chaudhry I, Farooqi A, Gadsby R, Heald A, et al. Minimising metabolic and cardiovascular risk in schizophrenia. *J Psychopharmacol* 2007; 21 (4): 357–73.
- Bech P, Vendsborg PJ, Rafaelson OJ. Lithium maintenance treatment of manic-melancholic patients: its role in the daily routine. *Acta Psychiatr Scand* 1976; 53: 70–81.
- Berken GH, Weinstein DO, Stern WC. Weight gain: a side effect of tricyclic antidepressants. *J Affect Disord* 1984; 7: 133–8.
- Bjorntorp P. Stress and cardiovascular disease. *Acta Physiol Scand Suppl* 1997; 640: 144–8.
- Bobes J, Arango C, Aranda P, Carmena R, García-García M, Rejas J, et al. Cardiovascular and metabolic risk in outpatients with schizophrenia treated with antipsychotics: results of the CLAMORS Study. *Schizophr Res* 2007; 90 (1–3): 162–73.
- Brown AD, Barton DA, Lambert GW. Cardiovascular abnormalities in patients with major depressive disorder: autonomic mechanisms and implications for treatment. *CNS Drugs* 2009; 23 (7): 583–602.
- Brown LC, Majumdar SR, Newman SC, Johnson JA. History of depression increases risk of type 2 diabetes in younger adults. *Diabetes Care* 2005; 28: 1063–7.
- Brown S. Excess mortality of schizophrenia. A meta-analysis. *Br J Psychiatry* 1997; 171: 502–8.
- Brown S, Inskip H, Barraclough B. Causes of the excess mortality of schizophrenia. *Br J Psychiatry* 2000; 177: 212–7.
- Bruggeman R, Schorr S, Van der Elst K, Postma M, Taxis K. Costeffectiveness of screening for diabetes in a cohort of patients with schizophrenia. *Schizophr Res* 2008; 102 (1–3): 161–2.
- Buckley PF, Miller DD, Singer B. Clinicians' recognition of the metabolic adverse effects of antipsychotic medications. *Schizophr Res* 2005; 79: 281–8.
- Bushe CJ, Leonard BE. Blood glucose and schizophrenia: a systematic review of prospective randomized clinical trials. *J Clin Psychiatry* 2007; 68 (11): 1682–90.
- Cahn W, Ramlal D, Bruggeman R, de Haan L, Scheepers FE, van Soest MM, et al. Prevention and treatment of somatic complications arising from the use of antipsychotics. *Tijdschr Psychiatr* 2008; 50 (9): 579–91.
- Canadian Diabetes Association. Clinical Practice Guidelines for the prevention and management of diabetes in Canada. *Can J Diabetes* 2008; 32 (Suppl. 1): S1–20.
- Capasso RM, Lineberry TW, Bostwick JM, Decker PA, St Sauver J. Mortality in schizophrenia and schizoaffective disorder: An

*Die englische Originalversion ist erschienen in *Eur Psychiatry* 2009;24:412–24.

^a Klinik für Psychiatrie, Katholische Universität, Leuven Campus Kortenberg, Leuvensesteenweg 517, 3070 Kortenberg, Belgien; E-Mail: marc.de.hert@uc-kortenberg.be

^b Abteilung für Epidemiologie und Biostatistik und EMGO, Institute for Health and Care Research, VU University Medical Centre, van der Boechorststraat 7, 1081 BT Amsterdam, Holland

^c National Heart and Lung Institute Cardiovascular Science, Imperial College, Charing Cross Campus, W6 8RP London, England

^d Klinik für Psychiatrie, Sozialpsychiatrie und Psychotherapie, Medizinische Hochschule Hannover, Carl-Neuberg-Straße, 1, 30625 Hannover, Deutschland

^e Endocrinology & Metabolism, Developmental Origins of Health and Disease, School of Medicine, University of Southampton, Southampton SO16 6YD, United Kingdom

^f Klinik für Psychiatrie und Psychotherapie, Ludwig-Maximilians-Universität, Nussbaumstraße 7, 80336 München, Deutschland

- Olmsted County, Minnesota cohort: 1950-2005. *Schizophr Res* 2008; 98 (1-3): 287-94.
25. Carnethon MR, Biggs ML, Barzilay JI, Smith NL, Vaccarino V, Bertoni AG, et al. Longitudinal Association Between Depressive Symptoms and Incident Type 2 Diabetes Mellitus in Older Adults. The Cardiovascular Health Study. *Arch Intern Med* 2007; 167: 801-8.
 26. Casey DE, Haupt DW, Newcomer JW, Henderson DC, Sernyak MJ, Davidson M, et al. Antipsychotic-Induced Weight Gain and Metabolic Abnormalities: Implications for Increased Mortality in Patients With Schizophrenia. *J Clin Psychiatry* 2004; 65 (Suppl. 7): 4-18.
 27. Cassidy F, Ahearn E, Carroll BJ. Elevated frequency of diabetes mellitus in hospitalized manic-depressive patients. *Am J Psychiatry* 1999; 156: 1417-20.
 28. Chrousos GP. The role of stress and the hypothalamic-pituitary-adrenal axis in the pathogenesis of the metabolic syndrome: neuroendocrine and target tissue-related causes. *Int J Obes* 2000; 24: S50-55.
 29. Citrome L. Risk-Benefit Analysis of Available Treatments for Schizophrenia. *Psychiatric Times* 2007; 1: 27-30.
 30. Citrome L, Holt RIG, Zachry WM, Clewell JD, Orth PA, Karagianis JL, et al. Risk of treatment-emergent diabetes mellitus in patients receiving antipsychotics. *Ann Pharmacother* 2007; 41: 1593-603.
 31. Citrome L, Yeomans D. Do guidelines for severe mental illness promote physical health and well-being? *J Psychopharmacol* 2005; 19 (6): 102-9.
 32. Cohen D, Huinink S. Atypical antipsychotic-induced diabetes mellitus in child and adolescent psychiatry. *CNS Drugs* 2007; 21 (12): 1035-8.
 33. Cohen D, Stolk RP, Grobbee DE, Gispen-de Wied CC. Hyperglycemia and diabetes in patients with schizophrenia or schizoaffective disorders. *Diabetes Care* 2006; 29 (4): 786-91.
 34. Cohn TA, Sernyak MJ. Metabolic monitoring for patients treated with antipsychotic medications. *Can J Psychiatry* 2006; 51: 492-501.
 35. Colton CW, Manderscheid RW. Congruencies in increased mortality rates, years of potential life lost, and causes of death among public mental health clients in eight states. *Prev Chronic Dis* 2006; 3: A42.
 36. Correll CU. Assessing and maximizing the safety and tolerability of antipsychotics used in the treatment of children and adolescents. *J Clin Psychiatry* 2008; 69 (Suppl. 4): 26-36.
 37. Correll CU. Balancing efficacy and safety in the treatment with antipsychotics. *CNS Spectr* 2007; 12 (Suppl. 17): 12-20.
 38. Correll CU, Frederickson AM, Kane JM, Manu P. Equally increased risk for metabolic syndrome in patients with bipolar disorder and schizophrenia treated with second-generation antipsychotics. *Bipolar Disord* 2008; 10: 788-97.
 39. Correll CU, Frederickson AM, Kane JM, Manu P. Metabolic syndrome and the risk of coronary heart disease in 367 patients treated with second-generation antipsychotic drugs. *J Clin Psychiatry* 2006; 67 (4): 575-83.
 40. Daniels SR, Greer FR, the Committee on Nutrition. Lipid Screening and Cardiovascular Health in Childhood. *Pediatrics* 2008; 122: 198-208.
 41. Daumit GL, Goff DC, Meyer JM, Davis VG, Nasrallah HA, McEvoy JP, et al. Antipsychotic effects on estimated 10-year coronary heart disease risk in the CATIE schizophrenia study. *Schizophr Res* 2008; 105: 175-87.
 42. De Hert M, van Eyck D, De Nayer A. Metabolic abnormalities associated with second generation antipsychotics: fact or fiction? Development of guidelines for screening and monitoring. *Int Clin Psychopharmacol* 2006; 21 (Suppl. 2): 11-5.
 43. De Hert M, van Winkel R, Van Eyck D, Hanssens L, Wampers M, Scheen A, et al. Prevalence of diabetes, metabolic syndrome and metabolic abnormalities in schizophrenia over the course of the illness: a cross-sectional study. *Clin Pract Epidemiol Ment Health* 2006; 2: 14. doi: 10.1186/1745-0179-2-14. online.
 44. De Hert M, Kalnicka D, van Winkel RM, Hanssens L, Van Eyck D, Wampers M, et al. Treatment with rosuvastatin for severe dyslipidemia in patients with schizophrenia and schizoaffective disorder. *J Clin Psychiatry* 2006; 67 (12): 1889-96.
 45. De Hert M, Falissard B, Mauri M, Shaw K, Wetterling T. Epidemiological study for the evaluation of metabolic disorders in patients with schizophrenia: The METEOR Study. *Eur Neuropsychopharmacol* 2008; 18 (Suppl. 4): S444.
 46. De Hert M, Schreurs V, Sweers K, Van Eyck D, Hanssens L, S' inko S, et al. Typical and atypical antipsychotics differentially affect long-term incidence rates of the metabolic syndrome in first-episode patients with schizophrenia: a retrospective chart review. *Schizophr Res* 2008; 101 (1-3): 295-303.
 47. De Hert M, Schreurs V, Vancampfort D, van Winkel R. Metabolic syndrome in people with schizophrenia: a review. *World Psychiatry* 2009; 8 (1): 15-22.
 48. De Nayer A, De Hert M, Scheen A, Van Gaal L, Peuskens J. Belgian consensus on metabolic problems associated with atypical antipsychotics. *Int J Clin Pract* 2005; 9: 130-7.
 49. Druss BG. Improving medical care for persons with serious mental illness: challenges and solutions. *J Clin Psych* 2007; 68 (Suppl. 4): 40-4.
 50. Eaton WW, Armenian H, Gallo J, Pratt L, Ford DE. Depression and risk for onset of type II diabetes. A prospective population-based study. *Diabetes Care* 1996; 19 (10): 1097-102.
 51. Falkai P, Wobrock T, Lieberman J, Glenthøj B, Gattaz WF, Möller HJ, et al. Guidelines for Biological Treatment of Schizophrenia. Part 1: Acute treatment of Schizophrenia. *World J Biol Psychiatry* 2005; 6 (3): 132-91.
 52. Farouhi NG, Balkau B, Borch-Johnsen K, Dekker J, Glumer C, Qiao Q, et al. The threshold for diagnosing impaired fasting glucose: a position statement by the European Diabetes Epidemiology Group. *Diabetologia* 2006; 49: 822-7.
 53. Faulkner G, Soundy AA, Lloyd K. Schizophrenia and weight management: a systematic review of interventions to control weight. *Acta Psychiatrica Scandinavica* 2003; 108: 324-32.
 54. Faulkner G, Cohn TA. Pharmacologic and nonpharmacologic strategies for weight gain and metabolic disturbance in patients treated with antipsychotic medications. *Can J Psychiatry* 2006; 51 (8): 502-11.
 55. Faulkner G, Cohn T, Remington G. Interventions to reduce weight gain in schizophrenia. *Schizophr Bull* 2007; 33 (3): 654-6.
 56. Faulkner G, Taylor A, Munro S, Selby P, Gee C. The acceptability of physical activity programming within a smoking cessation service for individuals with severe mental illness. *Patient Educ Couns* 2007; 66 (1): 123-6.
 57. Fenton WS, Stover ES. Mood disorders: cardiovascular and diabetes comorbidity. *Curr Opin Psychiatry* 2006; 19: 421-7.
 58. Fleischhacker WW, Cetkovich-Bakmas M, De Hert M, Hennekens C, Lambert M, Leucht S, et al. Comorbid somatic illnesses in patients with severe mental disorders: clinical, policy and research challenges. *J Clin Psychiatry* 2008; 69: 514-9.
 59. Fourth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice. European guidelines on cardiovascular disease prevention in clinical practice: executive summary. *Eur J Cardiovasc Prevent Rehabil* 2007; 14 (Suppl. 2): E1-40.
 60. Goff DC, Sullivan LM, McEvoy JP, Meyer J, Nasrallah H, Daumit G, et al. A comparison of ten-year cardiac risk estimates in schizophrenia patients from the CATIE study and matched controls. *Schizophr Res* 2005; 80 (1): 45-53.
 61. Haddad PM, Sharma SG. Adverse effects of atypical antipsychotics; Differential Risk and Clinical Implications. *CNS Drugs* 2007; 21: 911-36.
 62. Hanssens L, De Hert M, Kalnicka D, van Winkel R, Wampers M, Van Eyck D, et al. Pharmacological treatment of severe dyslipidaemia in patients with schizophrenia. *Int Clin Psychopharmacol* 2007; 22: 43-9.
 63. Haupt DW, Rosenblatt LC, Kim E, Baker RA, Whitehead R, Newcomer JW. Prevalence and predictors of lipid and glucose monitoring in commercially insured patients treated with second-generation antipsychotic agents. *Am J Psychiatry* 2009; 166 (3): 345-53.
 64. Henderson DC. Schizophrenia and comorbid metabolic disorders. *J Clin Psychiatry* 2005; 66 (Suppl. 6): 11-20.
 65. Hennekens CH. Schizophrenia and increased risks of cardiovascular disease. *Am Heart J* 2005; 151 (3): 598-603.
 66. Heuser I. The hypothalamic-pituitary-adrenal system in depression. *Pharmacopsychiatry* 1998; 31: 10-3.
 67. Hill Golden S, Lazo M, Carnethon M, Bertoni AG, Schreiner PJ, Diez Roux A, et al. Examining a Bidirectional Association Between Depressive Symptoms and Diabetes. *JAMA* 2008; 299 (23): 2751-9.

68. Holt RIG, Bushe C, Citrome L. Diabetes and schizophrenia 2005: are we any closer to understanding the link? *J Psychopharmacol* 2005; 19 (6): 56–65.
69. Holt RIG. Severe mental illness, antipsychotic drugs and the metabolic syndrome. *Br J Diab Vasc Disease* 2006; 6 (5): 199–204.
70. Holt RIG, Peveler RC. Antipsychotic drugs and diabetes – an application of the Austin Bradford Hill criteria. *Diabetologia* 2006; 49 (7): 1467–76.
71. Holt R, Peveler R. Obesity, serious mental illness and antipsychotic drugs. *Diabetes Obes Metab* 2009; 11 (7): 665–79.
72. Kahl KG, Bester M, Greggersen W, Rudolf S, Dibbelt L, Stoeckelhuber BM, et al. Visceral fat disposition and insulin sensitivity in depressed women with and without borderline personality disorder. *Psychosom Med* 2005; 67: 407–12.
73. Kahn RS, Fleischhacker WW, Boter H, Davidson M, Vergouwe Y, Keet I, et al. Effectiveness of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: an open randomised clinical trial. *Lancet* 2008; 371: 1085–97.
74. Katon WJ. The comorbidity of diabetes and depression. *Am J Med* 2008; 121 (11 Suppl. 2): S8–15.
75. Kinder LS, Carnethon MR, Palaniappan LP, King AC, Fortmann SP. Depression and the metabolic syndrome in young adults: Findings from the Third National Health and nutrition Examination Survey. *Psychosom Med* 2004; 66: 316–22.
76. Kinon BJ, Kaiser CJ, Ahmed S, Roteli M, Kolloack-Walker S. Association between early and rapid weight gain and change in weight over one year of olanzapine therapy in patients with schizophrenia and related disorders. *J Clin Psychopharmacol* 2005; 25 (3): 255–8.
77. Kissebah AH. Intra-abdominal fat: is it a major factor in developing diabetes and coronary artery disease? *Diab Res Clin Pract* 1996; 30: 25–30.
78. Knowler WC, Barrett-Connor E, Fowler SE, Hamman RF, Lachin JM, et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. *N Engl J Med* 2002; 346 (6): 393–403.
79. Kryzhanovskaya LA, Robertson-Plouch CK, Xu W, Carlson JL, Merida KM, Dittmann RW. The safety of olanzapine in adolescents with schizophrenia or bipolar I disorder: a pooled analysis of 4 clinical trials. *J Clin Psychiatry* 2009; 70 (2): 247–58.
80. Kumra S, Oberstar JV, Sikich L, Findling R, McClellan J, Vinogradoc S, et al. Efficacy and Tolerability of Second-Generation Antipsychotics in Children and Adolescents With Schizophrenia. *Schizophr Bull* 2008; 34: 60–71.
81. Lamberti JS, Crilly JF, Maharaj K, Olson D, Wiener K, Dvorin S, et al. Prevalence of diabetes mellitus among outpatients with severe mental disorders receiving atypical antipsychotic drugs. *J Clin Psychiatry* 2004; 65: 702–6.
82. Laursen TM, Munk-Olsen T, Agerbo E, Gasse C, Mortensen PB. Somatic hospital contacts, invasive cardiac procedures, and mortality from heart disease in patients with severe mental disorder. *Arch Gen Psychiatry* 2009; 66 (7): 713–20.
83. Lawrence DM, Holman CD, Jablensky AV, Hobbs MS. Death rate from ischemic heart disease in Western Australian psychiatric patients 1980–1998. *Br J Psychiatry* 2003; 182: 31–6.
84. Leucht S, Burkard T, Henderson J, Maj M, Sartorius N. Physical illness and schizophrenia. *Acta Psychiatr Scand* 2007; 116 (5): 317–33.
85. Leucht S, Corves C, Arbtter D, Engel RR, Li C, Davis JM. Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis. *Lancet* 2009; 373 (9657): 31–41.
86. Lieberman JA, Stroup TS, McEvoy JP, Swartz MS, Rosenheck RA, Perkins DO, et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. *N Engl J Med* 2005; 353 (12): 1209–23.
87. Mackin P, Bishop D, Watkinson H. A prospective study of monitoring practices for metabolic disease in antipsychotic-treated community psychiatric patients. *BMC Psychiatry* 2007; 25: 7–28.
88. Maina G, Salvi V, Vitalucci A, D'Ambrosio V, Bogetto F. Prevalence and correlates of overweight in drug-naïve patients with bipolar disorders. *J Affect Disord* 2008; 110: 149–55.
89. Mancia G, De Backer G, Dominiczak A, Cifkova R, Fagard R, Germon G, et al. Guidelines for the management of arterial hypertension. *Eur Heart J* 2007; 28: 1462–536.
90. Marder SR, Essock SM, Miller AL, Buchanan RW, Casey DE, Davis JM, et al. Physical health monitoring of patients with schizophrenia. *Am J Psychiatry* 2004; 161: 1334–49.
91. McIntyre RS, Konarski JZ, Misener VL, Kennedy SH. Bipolar disorder and diabetes mellitus: epidemiology, etiology, and treatment implications. *Ann Clin Psychiatry* 2005; 17 (2): 83–93.
92. McIntyre RS, Sozycynska JK, Konarski JZ, Kennedy SH. The effect of antidepressants on glucose homeostasis and insulin sensitivity: synthesis and mechanisms. *Expert Opin Drug Saf* 2006; 5: 157–68.
93. Meyer JM, Davis VG, Goff DC, McEvoy J, Nasrallah H, Davis S, et al. Change in metabolic syndrome parameters with antipsychotic treatment in the CATIE Schizophrenia Trial: Prospective data from phase 1. *Schizophr Res* 2008; 101 (1-3): 273–86.
94. Meyer JM, Stahl SM. The metabolic syndrome and schizophrenia. *Acta Psychiatr Scand* 2009; 119 (1): 4–14.
95. Miller LJ. Management of Atypical Antipsychotic Drug-Induced Weight Gain Focus on Metformin Pharmacotherapy 2009; 29 (6): 725–35.
96. Nasrallah HA, Meyer JM, Goff DC, McEvoy JP, Davis SM, Stroup TS, et al. Low rates of treatment for hypertension, dyslipidemia and diabetes in schizophrenia: data from the CATIE schizophrenia trial sample at baseline. *Schizophr Res* 2006; 86 (1-3): 15–22.
97. Nasrallah HA. Atypical antipsychotic-induced metabolic side effects: insights from receptor-binding profiles. *Mol Psychiatry* 2008; 13: 27–35.
98. Nathan DM, Davidson MB, DeFronzo RA, Heine RJ, Henry RR, et al. Impaired fasting glucose and impaired glucose tolerance: implications for care. *Diabetes Care* 2007; 30: 753–9.
99. Newcomer JW, Nasrallah HA, Loebel AD. The atypical antipsychotic therapy and metabolic issues national survey. *J Clin Psychopharmacol* 2004; 24: 1–6.
100. Newcomer JW. Second-Generation (Atypical) Antipsychotics and Metabolic Effects. A Comprehensive Literature Review. *CNS Drugs* 2005; 19 (Suppl. 1): 1–93.
101. Newcomer JW. Antipsychotic medications: metabolic and cardiovascular risk. *J Clin Psychiatry* 2007; 68 (Suppl. 4): 8–13.
102. NICE. Schizophrenia Core interventions in the treatment and management of schizophrenia in adults in primary and secondary care. 2008; online: <http://www.nice.org.uk/guidance/index.jsp?action=download&o=42139> (site consulted on 1st July 2009).
103. Nicol G, Haupt D, Flavin K, Schweiger J, Hessler M, Hessler E, et al. Preliminary results of the MEAC study: metabolic effects of antipsychotics in children. *Schizophr Bull* 2009; 35 (Suppl. 1): 32.
104. Osborn DP, Levy G, Nazareth I, Petersen I, Islam A, King MB. Relative risk of cardiovascular and cancer mortality in people with severe mental illness from the United Kingdom's General Practice Research Database. *Arch Gen Psychiatry* 2007; 64 (2): 242–9.
105. Osborn DP, Wright CA, Levy G, King MB, Deo R, Nazareth I. Relative risk of diabetes, dyslipidaemia, hypertension and the metabolic syndrome in people with severe mental illnesses: systematic review and meta-analysis. *BMC Psychiatry* 2008; 8: 84. 25.
106. Ösby U, Correia N, Brandt L, Ekblom A, Sparen P. Mortality and causes of death in schizophrenia in Stockholm county, Sweden. *Schizophr Res* 2000; 45 (1-2): 21–8.
107. Ösby U, Correia N, Brandt L, Ekblom A, Sparen P. Time trends in schizophrenia mortality in Stockholm County, Sweden: cohort study. *BMJ* 2000; 321 (7259): 483–4.
108. Peiris AN, Sothmann MS, Hoffmann RG, Hennes MI, Wilson CR. Adiposity, fat distribution, and cardiovascular risk. *Ann Int Med* 1989; 110: 867–72.
109. Pratt L, Ford D, Crum R, Armenian H, Gallo J, Eaton W. Depression, Psychotropic Medication, and Risk of Myocardial Infarction. *Circulation* 1996; 94: 3123–9.
110. Ray WA, Chung CP, Murray KT, Hall K, Stein CM. Atypical antipsychotic drugs and the risk of sudden cardiac death. *N Engl J Med* 2009; 360 (3): 225–35.
111. Rozanski A, Blumenthal JA, Kaplan J. Impact of psychological factors on the pathogenesis of cardiovascular disease and implications for therapy. *Circulation* 1999; 99: 2192–217.
112. Rubin RR, Ma Y, Marrero DG, Peyrot M, Barret-Conner EL, Kahn SE, et al. Elevated depression symptoms, antidepressant medi-

- ne use, and risk of developing diabetes during the diabetes prevention program. *Diabetes Care* 2008; 31: 420–6.
113. Saha S, Chant D, McGrath J. A Systematic Review of Mortality in Schizophrenia. *Arch Gen Psychiatry* 2007; 64: 1123–31.
 114. Sahota DP, Knowler W, Looker H. Depression, diabetes and glycemic control in an American Indian Community. *J Clin Psychiatry* 2008; 69 (5): 800–9.
 115. Sáiz Ruiz J, Bobes García J, Vallejo Ruiloba J, Giner Ubago J, García-Portilla González MP. Consensus on physical health of patients with schizophrenia from the Spanish Societies of Psychiatry and Biological Psychiatry. *Actas Esp Psiquiatr* 2008; 36 (5): 251–64.
 116. Scheen AJ, De Hert MA. Abnormal glucose metabolism in patients treated with antipsychotics. *Diabetes Metab* 2007; 33: 169–75.
 117. Scheen A, van Winkel R, De Hert M. Traitement neuroleptique et troubles métaboliques. *Med Mal Metabol* 2008; 2 (6): 593–9.
 118. Simon V, vanWinkel R, De Hert M. Are weight gain and metabolic sideeffects of atypical antipsychotics dose-dependent? A Literature review. *J Clin Psychiatry* 2009; 70 (7): 1041–50.
 119. Smith M, Hokins D, Peveler R, Holt R, Woodward M, Ismail K. First- versus second generation antipsychotics and risk for diabetes in schizophrenia: systematic review and meta-analysis. *Br J Psychiatry* 2008; 192 (6): 406–11.
 120. Smith RC, Lindenmayer JP, Davis JM, Cornwell J, Noth K, Gupta S, et al. Cognitive and antismoking effects of varenicline in patients with schizophrenia or schizoaffective disorder. *Schizophr Res* 2009; 110 (1–3): 149–55.
 121. Stahl SM, Mignon L, Meyer JM. Which comes first: atypical antipsychotic treatment or cardiometabolic risk? *Acta Psychiatr Scand* 2009; 119 (3): 171–9.
 122. Stroup TS, Lieberman JA, McEvoy JP, Swartz MS, Davis SM, Rosenheck RA, et al. Effectiveness of olanzapine, quetiapine, risperidone, and ziprasidone in patients with chronic schizophrenia following discontinuation of a previous atypical antipsychotic. *Am J Psychiatry* 2006; 163 (4): 611–22.
 123. Stunkard AJ, Myles MS, Allison KC. Depression and obesity. *Biol Psychiatry* 2003; 54: 330–7.
 124. Surtees PG, Wainwright NWJ, Luben RN, Wareham NJ, Bingham SA, Khaw S. Depression and ischemic Heart Disease Mortality: Evidence From the EPIC-Norfolk United Kingdom Prospective Cohort Study. *Am J Psychiatry* 2008; 165: 515–23.
 125. Taxis K, Schorr S, Fouchier M, Slooff C, Bruggeman R. Is it appropriate to use cardiovascular risk scores in patients with psychotic disorders? *Schizophr Res* 2008; 102 (1–3): 169.
 126. Thakore JH, Richards PJ, Reznick RH, Martin A, Dinan TG. Increased intra-abdominal fat deposition in patients with major depressive illness as measured by computer tomography. *Biol Psychiatry* 1997; 41: 1140–2.
 127. Thakore JH, Mann JN, Vlahos I, Martin A, Reznick RH. Increased visceral fat distribution in drug-naive and drug-free patients with schizophrenia. *Int J Obes* 2002; 26: 137–41.
 128. Tiihonen J, Wahlbeck K, Lönnqvist J, Klaukka T, Ioannidis JP, Volavka J, et al. Effectiveness of antipsychotic treatments in a nationwide cohort of patients in community care after first hospitalisation due to schizophrenia and schizoaffective disorder: observational follow-up study. *BMJ* 2006; 333 (7561): 224 (Epub 2006 Jul 6).
 129. The international expert committee. International Expert Committee Report on the Role of the A1C Assay in the Diagnosis of Diabetes. *Diabetes Care* 2009; 32: 1327–L1334. doi: 10.2337/dc09-9033.
 130. Tschoner A, Engl J, Laimer MS, Rettenbacher M, Fleischhacker W, et al. Metabolic side effects of antipsychotic medication. *Int J Clin Pract* 2007; 61 (8): 1356–70.
 131. Tuomilehto J, Lindström J, Eriksson JG, Valle TT, Hämäläinen H, et al. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. *N Engl J Med* 2001; 344 (18): 1343–50.
 132. Ussher MH, Taylor A, Faulkner G. Exercise interventions for smoking cessation. *Cochrane Database Syst Rev* 2008; 4: CD002295.
 133. vanWinkel R, De Hert M, Van Eyck D, Hanssens L, Wampers M, Scheen A, et al. Screening for diabetes and other metabolic abnormalities in patients with schizophrenia and schizoaffective disorder: evaluation of incidence and screening methods. *J Clin Psychiatry* 2006; 67 (10): 1493–500.
 134. vanWinkel R, De Hert M, Wampers M, Van Eyck D, Hanssens L, Scheen A, et al. Major changes in glucose metabolism including new-onset diabetes within 3 months after initiation or switch of atypical antipsychotic medication in patients with schizophrenia and schizoaffective disorder. *J Clin Psychiatry* 2008; 69: 472–9.
 135. van Winkel R, De Hert M, Van Eyck D. Prevalence of diabetes and the metabolic syndrome in a sample of patients with bipolar disorder. *Bipolar Disord* 2008; 10: 342–8.
 136. van Winkel R, van Os J, Celic I, Van Eyck D, Wampers M, Scheen A, et al. Psychiatric diagnosis as an independent risk factor for metabolic disturbance. Results from a comprehensive, naturalistic screening program. *J Clin Psychiatry* 2008; 69 (8): 1319–27.
 137. Waterreus AJ, Laugharne JD. Screening for the metabolic syndrome in patients receiving antipsychotic treatment: a proposed algorithm. *Med J Aust* 2009; 190 (4): 185–9.
 138. World Health Organisation: Definition and diagnosis of diabetes mellitus and intermediate hyperglycaemia –Report of a WHO/IDF Consultation, 2006.
 139. Wu RR, Zhao JP, Liu ZN, Zhai JG, Guo XF, Guo WB, et al. Effects of typical and atypical antipsychotics on glucose-insulin homeostasis and lipid metabolism in first-episode schizophrenia. *Psychopharmacology* 2006; 186 (4): 572–8.
 140. Wu RR, Zhao JP, Jin H, Shao P, Fang MS, Guo XF, et al. Lifestyle intervention and metformin for treatment of antipsychotic-induced weight gain: a randomized controlled trial. *JAMA* 2008; 299 (2): 185–93.
 141. Zimmermann U, Kraus T, Himmerich H, Schuld A, Pollmächer T. Epidemiology, implications and mechanisms underlying drug-induced weight gain in psychiatric patients. *J Psychiatr Res* 2003; 37: 193–220